Acquisition of human immunodeficiency virus infection in a patient with multiple sclerosis: could these conditions positively influence each other's course?
Adult
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes
/ drug effects
Female
Glatiramer Acetate
/ therapeutic use
HIV
/ genetics
HIV Infections
/ diagnostic imaging
Humans
Immunologic Factors
/ therapeutic use
Magnetic Resonance Imaging
Multiple Sclerosis, Relapsing-Remitting
/ diagnostic imaging
Natalizumab
/ therapeutic use
RNA, Viral
/ genetics
Viral Load
/ drug effects
Viremia
/ diagnostic imaging
HIV
Multiple sclerosis
Natalizumab
Relapsing-remitting MS
Viral load
cART
Journal
Journal of neurovirology
ISSN: 1538-2443
Titre abrégé: J Neurovirol
Pays: United States
ID NLM: 9508123
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
22
01
2020
accepted:
24
06
2020
revised:
10
06
2020
pubmed:
17
7
2020
medline:
30
10
2021
entrez:
17
7
2020
Statut:
ppublish
Résumé
Patients with human immunodeficiency virus (HIV) infection have a decreased risk of developing multiple sclerosis (MS) and MS patients very rarely contract HIV infection. We report on a 35-year-old woman with relapsing-remitting MS, who acquired HIV infection 8 years after MS onset. During 7 years of follow-up without combined antiretroviral therapy (cART), CD4+ counts decreased and HIV viremia increased progressively, but slightly. These trends reverted after starting cART, with optimal viro-immunological control. While the patient had many MS relapses before acquiring HIV infection, she had then only one relapse, shortly after HIV infection, despite irregular or no MS therapy. This case contributes to the discussion about MS and HIV potential interactions and describes for the first time the effects of the MS-targeting drug natalizumab in an HIV-positive patient.
Identifiants
pubmed: 32671809
doi: 10.1007/s13365-020-00876-7
pii: 10.1007/s13365-020-00876-7
doi:
Substances chimiques
Immunologic Factors
0
Natalizumab
0
RNA, Viral
0
Glatiramer Acetate
5M691HL4BO
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM